| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 21 | 抗病毒化合物 | CN201080003465.2 | 2010-06-10 | CN102333772B | 2013-12-11 | D·A·德格; W·M·凯蒂; C·W·哈钦斯; P·L·唐纳; A·C·克吕格; C·E·莫特; L·T·奈尔逊; S·V·帕特尔; M·A·马图伦科; R·G·克迪; T·K·金克森; D·K·哈钦森; C·A·弗伦特格; R·沃纳; C·J·马林; M·D·图法诺; D·A·贝特本纳; T·W·罗克维; 刘大春; J·K·普拉特; K·萨里斯; K·R·沃勒; S·H·瓦高; J·C·卡利法诺; 李文珂; M·E·贝利兹; D·D·凯斯皮; J·T·伦道夫; 高忆 |
| 本发明描述了有效抑制丙型肝炎病毒(“HCV”)的复制的化合物。本发明还涉及制备这样的化合物的方法，含有这样的化合物的组合物，和使用这样的化合物来治疗HCV感染的方法。 | ||||||
| 22 | 抗病毒化合物 | CN201080003465.2 | 2010-06-10 | CN102333772A | 2012-01-25 | D·A·德格; W·M·凯蒂; C·W·哈钦斯; P·L·唐纳; A·C·克吕格; C·E·莫特; L·T·奈尔逊; S·V·帕特尔; M·A·马图伦科; R·G·克迪; T·K·金克森; T·N·索尔特维德尔; D·K·哈钦森; C·A·弗伦特格; R·沃纳; C·J·马林; M·D·图法诺; D·A·贝特本纳; T·W·罗克维; 刘大春; J·K·普拉特; M·J·莱文; K·萨里斯; K·R·沃勒; S·H·瓦高; J·C·卡利法诺; 李文珂; M·E·贝利兹; D·D·凯斯皮; J·T·伦道夫 |
| 描述了有效抑制丙型肝炎病毒(“HCV”)的复制的化合物。本发明还涉及制备这样的化合物的方法，含有这样的化合物的组合物，和使用这样的化合物来治疗HCV感染的方法。 | ||||||
| 23 | 抗菌剂 | CN201110144246.2 | 2004-01-08 | CN102267924A | 2011-12-07 | N·H·安德森; J·宝曼; A·欧文; E·哈伍德; T·克林; K·姆德鲁利; S·恩吉; K·B·普菲斯特; R·肖瓦; A·旺曼; A·亚巴娜发 |
| 本发明提供通式I的抗菌化合物：以及它们的立体异构体，药学上可接受的盐、酯和它们的前药；含有所述化合物的药物组合物；通过给予所述化合物治疗细菌感染的方法；以及制备该化合物的步骤。 | ||||||
| 24 | 三取代的杂芳基以及制备方法和其用途 | CN03812699.0 | 2003-04-04 | CN100448868C | 2009-01-07 | 李文成; 孙立红; 山峰; 克劳迪奥·楚亚奎; 郑忠立; 拉塞尔·C·彼得 |
| 式I化合物具有意想不到的对Alk5和/或Alk4的高亲和性，并且可用作预防和/或治疗大量疾病包括纤维变性病症的拮抗剂。在一个实施方案中，本发明涉及通式I的化合物。 | ||||||
| 25 | 三取代的杂芳基以及制备方法和其用途 | CN03812699.0 | 2003-04-04 | CN1658866A | 2005-08-24 | 李文成; 孙立红; 山峰; 克劳迪奥·楚亚奎; 郑忠立; 拉塞尔·C·彼得 |
| 式I化合物具有意想不到的对Alk5和/或Alk4的高亲和性，并且可用作预防和/或治疗大量疾病包括纤维变性病症的拮抗剂。在一个实施方案中，本发明涉及通式I的化合物。 | ||||||
| 26 | Asymmetric synthesis of funapide | US15625173 | 2017-06-16 | US10100060B2 | 2018-10-16 | Ronen Ben-David; Jian Chen; Michael A. Christie; Mina Gadelrab Dimitri; Graciela Noemi Gershon; Linli He; Nelson G. Landmesser; Daniel V. Levy; Orel Yosef Mizrahi; Partha S. Mudipalli; Harlan F. Reese; Joseph A. Sclafani; Yi Wang |
| This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. | ||||||
| 27 | Anti-viral compounds | US15431069 | 2017-02-13 | US10039754B2 | 2018-08-07 | Mary E. Bellizzi; David A. Betebenner; Jean-Christophe C. Califano; William A. Carroll; Daniel D. Caspi; David A. DeGoey; Pamela L. Donner; Charles A. Flentge; Yi Gao; Charles W. Hutchins; Douglas K. Hutchinson; Tammie K. Jinkerson; Warren M. Kati; Ryan G. Keddy; Allan C. Krueger; Wenke Li; Dachun Liu; Clarence J. Maring; Mark A. Matulenko; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; John K. Pratt; John T. Randolph; Todd W. Rockway; Kathy Sarris; Michael D. Tufano; Seble H. Wagaw; Rolf Wagner; Kevin R. Woller |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
| 28 | GEMINAL SUBSTITUTED QUINUCLIDINE AMIDE COMPOUNDS AS AGONISTS OF ALPHA-7 NICOTONIC ACETYLCHOLINE RECEPTORS | US15536073 | 2015-12-14 | US20170369486A1 | 2017-12-28 | Raksha ACHARYA; Duane A. BURNETT; Matthew Gregory BURSAVICH; Andrew Simon COOK; Bryce Alden HARRISON; Gerhard KOENIG; Andrew J. MCRINER |
| The present invention relates to novel geminal substituted quinuclidine amide compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom. | ||||||
| 29 | Anti-Viral Compounds | US15431069 | 2017-02-13 | US20170157104A1 | 2017-06-08 | Mary E. Bellizzi; David A. Betebenner; Jean-Christophe C. Califano; William A. Carroll; Daniel D. Caspi; David A. DeGoey; Pamela L. Donner; Charles A. Flentge; Yi Gao; Charles W. Hutchins; Douglas K. Hutchinson; Tammie K. Jinkerson; Warren M. Kati; Ryan G. Keddy; Allan C. Krueger; Wenke Li; Dachun Liu; Clarence J. Maring; Mark A. Matulenko; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; John K. Pratt; John T. Randolph; Todd W. Rockway; Kathy Sarris; Michael D. Tufano; Seble H. Wagaw; Rolf Wagner; Kevin R. Woller |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
| 30 | 3,5-DICHLORO,4-(3,4-(CYCLO-)ALKOXYPHENYL)--2-CARBONYLOXY)ETHYL)PYRIDINE DERIVATIVES AS PDE-4 INHIBITORS | US15316401 | 2014-06-04 | US20170152256A1 | 2017-06-01 | Gabriele AMARI; Elisabetta ARMANI; Mauro RICCABONI; Andrea RIZZI; Charles BAKER-GLENN; Wesley BLACKABY; Herve VAN DE POEL; Ben WHITTAKER |
| The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. | ||||||
| 31 | Salt forms of (S)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate | US14776432 | 2014-03-14 | US09518049B2 | 2016-12-13 | Craig S. Siegel; Jin Zhao |
| The present invention relates to novel salt forms of (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate useful as an inhibitor of glucosylceramide synthase (GCS) and for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | ||||||
| 32 | Glucosylceramide synthase inhibitors | US14030725 | 2013-09-18 | US09139580B2 | 2015-09-22 | Elyse Bourque; Bradford Hirth; Renato Sklerj; Elina Makino; Fazeela Morshed; Lingyun Li; Paul Mason; John P. Leonard; James Lillie; Hanlan Liu; Mary A. Cromwell; Bing Wang; Thomas O'Shea |
| The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | ||||||
| 33 | Compounds | US14097693 | 2013-12-05 | US09090606B2 | 2015-07-28 | Elisabetta Armani; Gabriele Amari; Mauro Riccaboni; Charles Baker-Glenn |
| Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction. | ||||||
| 34 | 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | US13211678 | 2011-08-17 | US09045468B2 | 2015-06-02 | Peter R. Guzzo; Shuang Liu; Kristen N. Ryan; Bruce F. Molino; Russell DeOrazio; Richard E. Olson; John E. Macor |
| The compounds of the present invention are represented by the following 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives having formula (I): where the carbon atom designated * is in the R or S configuration when n is 1 and the substituents X and R1-R7 are as defined herein. | ||||||
| 35 | Anti-viral compounds | US12964027 | 2010-12-09 | US08921514B2 | 2014-12-30 | David A. DeGoey; Warren M. Kati; Charles W. Hutchins; Pamela L. Donner; Allan C. Krueger; John T. Randolph; Christopher E. Motter; Lissa T. Nelson; Sachin V. Patel; Mark A. Matulenko; Ryan G. Keddy; Tammie K. Jinkerson; Yi Gao; Dachun Liu; John K. Pratt; Todd W. Rockway; Clarence J. Maring; Douglas K. Hutchinson; Charles A. Flentge; Rolf Wagner; Michael D. Tufano; David A. Betebenner; Kathy Sarris; Kevin R. Woller; Seble H. Wagaw; Jean C. Califano; Wenke Li; Daniel D. Caspi; Mary E. Bellizzi; William A. Carroll |
| Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | ||||||
| 36 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | US14471958 | 2014-08-28 | US20140371460A1 | 2014-12-18 | Elyse BOURQUE; Cassandra CELATKA; Bradford HIRTH; Markus METZ; Zhong ZHAO; Renato SKLERJ; Yibin XIANG; Katherine JANCSICS; John MARSHALL; Seng CHENG; Ronald SCHEULE; Mario CABRERA-SALAZAR; Andrew GOOD |
| The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | ||||||
| 37 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | US14030725 | 2013-09-18 | US20140255381A1 | 2014-09-11 | Elyse BOURQUE; Cassandra CELATKA; Bradford HIRTH; Markus METZ; Zhong ZHAO; Renato SKLERJ; Yibin XIANG; Katherine JANCSICS; John MARSHALL; Seng CHENG; Ronald SCHEULE; Mario CABRERA-SALAZAR; Andrew GOOD |
| The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. | ||||||
| 38 | NOVEL COMPOUNDS | US14097693 | 2013-12-05 | US20140155428A1 | 2014-06-05 | Elisabetta ARMANI; Gabriele Amari; Mauro Riccaboni; Charles Baker-Glenn |
| Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction. | ||||||
| 39 | COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE | US13623962 | 2012-09-21 | US20130281445A1 | 2013-10-24 | Simon Everitt; Ronald Knegtel; Michael Mortimore; Alistair Rutherford |
| The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | ||||||
| 40 | Compounds for the Treatment of Hepatitis C | US13166926 | 2011-06-23 | US20110256099A1 | 2011-10-20 | Kap-Sun Yeung; Kyle E. Parcella; John A. Bender; Brett R. Beno; Katharine A. Grant-Young; Ying Han; Piyasena Hewawasam; John F. Kadow; Andrew Nickel |
| The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | ||||||
QQ群二维码
意见反馈
意见反馈